<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10107">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691197</url>
  </required_header>
  <id_info>
    <org_study_id>AG9689-002</org_study_id>
    <nct_id>NCT00691197</nct_id>
  </id_info>
  <brief_title>Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear</brief_title>
  <official_title>Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Testing the Safety and Acceptability of Using a Rewetting Drop with Contact Lenses
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>Change from Baseline at Day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of Subjects Tabulated by Changes in Line Number at Day 90 from Baseline; Visual Acuity measured by LogMar reported as Snellen equivalents. Better: an increase of 2 lines or more in at least one eye; No Change: a change less than +/- 2 lines in both eyes; Worse: a decrease of 2 lines or more in at least one eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal Staining</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Corneal staining of greater or equal to grade 2 at day 90. Grading scale: 0 = None Present; 1 = Trace Finding; 2 = Mild Finding; 3 = Moderate Finding; 4 = Severe Finding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Ametropia</condition>
  <arm_group>
    <arm_group_label>Carboxymethylcellulose sodium and Glycerin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboxymethylcellulose sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboxymethylcellulose sodium based rewetting drop</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Carboxymethylcellulose sodium and Glycerin</intervention_name>
    <description>Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.</description>
    <arm_group_label>Carboxymethylcellulose sodium and Glycerin</arm_group_label>
    <other_name>Optive™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Carboxymethylcellulose sodium</intervention_name>
    <description>Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.</description>
    <arm_group_label>Carboxymethylcellulose sodium</arm_group_label>
    <other_name>Refresh Contacts®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adapted contact lens wearer

        Exclusion Criteria:

          -  Monovision lens wearer, ocular or systemic disease, pregnant or planning to become
             pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 26, 2015</lastchanged_date>
  <firstreceived_date>March 4, 2008</firstreceived_date>
  <firstreceived_results_date>November 6, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Therapeutic Area Head</name_title>
    <organization>Allergan</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carboxymethylcellulose Sodium and Glycerin</title>
          <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
        </group>
        <group group_id="P2">
          <title>Carboxymethylcellulose Sodium</title>
          <description>Carboxymethylcellulose sodium based rewetting drop</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carboxymethylcellulose Sodium and Glycerin</title>
          <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
        </group>
        <group group_id="B2">
          <title>Carboxymethylcellulose Sodium</title>
          <description>Carboxymethylcellulose sodium based rewetting drop</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="166"/>
                <measurement group_id="B2" value="80"/>
                <measurement group_id="B3" value="246"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="37.6" spread="11.94"/>
                <measurement group_id="B2" value="36.8" spread="11.54"/>
                <measurement group_id="B3" value="37.4" spread="11.80"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="122"/>
                <measurement group_id="B2" value="53"/>
                <measurement group_id="B3" value="175"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="71"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best Corrected Visual Acuity</title>
        <description>Percentage of Subjects Tabulated by Changes in Line Number at Day 90 from Baseline; Visual Acuity measured by LogMar reported as Snellen equivalents. Better: an increase of 2 lines or more in at least one eye; No Change: a change less than +/- 2 lines in both eyes; Worse: a decrease of 2 lines or more in at least one eye.</description>
        <time_frame>Change from Baseline at Day 90</time_frame>
        <safety_issue>No</safety_issue>
        <population>Completed Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose Sodium and Glycerin</title>
            <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Sodium</title>
            <description>Carboxymethylcellulose sodium based rewetting drop</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="155"/>
                  <measurement group_id="O2" value="75"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Best Corrected Visual Acuity</title>
            <description>Percentage of Subjects Tabulated by Changes in Line Number at Day 90 from Baseline; Visual Acuity measured by LogMar reported as Snellen equivalents. Better: an increase of 2 lines or more in at least one eye; No Change: a change less than +/- 2 lines in both eyes; Worse: a decrease of 2 lines or more in at least one eye.</description>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Better</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.65"/>
                  <measurement group_id="O2" value="1.33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.06"/>
                  <measurement group_id="O2" value="98.67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Worse</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.29"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Patient Acceptability</title>
        <description>A questionnaire was administered to all patients to evaluate the acceptability of the Rewetting Drops (RD) with use with Contact Lenses (CL). Table below shows the percentage of participants responding either &quot;Agree&quot; or &quot;Strongly Agree&quot; at day 90. Number of participants answering question is indicated as (number of Test subjects/number of Control subjects)</description>
        <time_frame>Day 90</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose Sodium and Glycerin</title>
            <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Sodium</title>
            <description>Carboxymethylcellulose sodium based rewetting drop</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="161"/>
                  <measurement group_id="O2" value="79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patient Acceptability</title>
            <description>A questionnaire was administered to all patients to evaluate the acceptability of the Rewetting Drops (RD) with use with Contact Lenses (CL). Table below shows the percentage of participants responding either &quot;Agree&quot; or &quot;Strongly Agree&quot; at day 90. Number of participants answering question is indicated as (number of Test subjects/number of Control subjects)</description>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Liked using the RD (160/78)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72.5"/>
                  <measurement group_id="O2" value="82.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RD gave good comfort during day (161/79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78.8"/>
                  <measurement group_id="O2" value="84.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RD on CL gave good initial comfort (161/79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49.0"/>
                  <measurement group_id="O2" value="54.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At day's end,CL felt better after RD use (161/78)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="51.6"/>
                  <measurement group_id="O2" value="62.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Could wear CL longer when using RD (161/79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46.6"/>
                  <measurement group_id="O2" value="44.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vision was normal soon after using RD (161/79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85.7"/>
                  <measurement group_id="O2" value="81.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vision with CL was better after RD use (161/79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31.0"/>
                  <measurement group_id="O2" value="41.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Would likely purchase these RD (161/79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50.4"/>
                  <measurement group_id="O2" value="68.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Eyes felt better after CL removal (161/79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38.5"/>
                  <measurement group_id="O2" value="43.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Staining</title>
        <description>Corneal staining of greater or equal to grade 2 at day 90. Grading scale: 0 = None Present; 1 = Trace Finding; 2 = Mild Finding; 3 = Moderate Finding; 4 = Severe Finding</description>
        <time_frame>Day 90</time_frame>
        <safety_issue>No</safety_issue>
        <population>Completed Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose Sodium and Glycerin</title>
            <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Sodium</title>
            <description>Carboxymethylcellulose sodium based rewetting drop</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="155"/>
                  <measurement group_id="O2" value="75"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Corneal Staining</title>
            <description>Corneal staining of greater or equal to grade 2 at day 90. Grading scale: 0 = None Present; 1 = Trace Finding; 2 = Mild Finding; 3 = Moderate Finding; 4 = Severe Finding</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Patient Preference</title>
        <description>Percentage of patients who used pre-study rewetting drops and answered “Agree” or “Strongly Agree” when asked if they preferred the study drops (SD) over their pre-study drops(PSD).</description>
        <time_frame>Day 30</time_frame>
        <safety_issue>No</safety_issue>
        <population>Responders Completed Population</population>
        <group_list>
          <group group_id="O1">
            <title>Carboxymethylcellulose Sodium and Glycerin</title>
            <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
          </group>
          <group group_id="O2">
            <title>Carboxymethylcellulose Sodium</title>
            <description>Carboxymethylcellulose sodium based rewetting drop</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patient Preference</title>
            <description>Percentage of patients who used pre-study rewetting drops and answered “Agree” or “Strongly Agree” when asked if they preferred the study drops (SD) over their pre-study drops(PSD).</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Prefer SD over PSD</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47.2"/>
                  <measurement group_id="O2" value="41.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SD more comfortable overall than PSD</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53.2"/>
                  <measurement group_id="O2" value="34.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Carboxymethylcellulose Sodium and Glycerin</title>
          <description>Carboxymethylcellulose sodium and Glycerin based rewetting drop</description>
        </group>
        <group group_id="E2">
          <title>Carboxymethylcellulose Sodium</title>
          <description>Carboxymethylcellulose sodium based rewetting drop</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Conjunctival oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Episcleritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Limbal hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 90 days from the time submitted to the sponsor for review.
The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>(714)246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
